| Name | Title | Contact Details |
|---|---|---|
Sean Hennigan |
Director of IT | Profile |
Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and other inflammatory and immunology indications with high unmet need. Apogee`s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company`s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today`s standard of care.
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...
Vidara Therapeutics is a Alpharetta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.
Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.